A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease.
Johnson AM, Askar M, Belani S, Khan A, Xu AA, Kassmeyer B, Said H, Santiago-Castro M, Devi J, Huang K, Jaiprada F, Seth N, Dulaney D, Loftus EV Jr, Fenster M, Patel A, Bishu S, Ungaro RC, Shukla R, Yarur AJ, Deepak P.
Johnson AM, et al.
J Crohns Colitis. 2025 May 8;19(5):jjaf070. doi: 10.1093/ecco-jcc/jjaf070.
J Crohns Colitis. 2025.
PMID: 40289770
Free PMC article.
Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of 4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn's Disease of 0-1 or abse …
Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of 4 or physician global assessment in those without …